The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.
Toshiki OkaKoji HatanoYohei OkudaAkinaru YamamotoToshihiro UemuraGaku YamamichiEisuke TomiyamaYu IshizuyaYoshiyuki YamamotoTaigo KatoAtsunari KawashimaKazutoshi FujitaNorio NonomuraPublished in: International journal of clinical oncology (2022)
Time to CRPC and lymph node metastasis were predictors of the PSA response rate and PSA-PFS.